Maha discusses the critical areas of healthcare investment, highlighting the need for innovation in anti-infectives and immuno-oncology. She emphasizes the challenges faced by big pharma in producing groundbreaking companies, leading to a cycle of acquisitions. Selectivity in funding is crucial, as not all sectors are worth pursuing due to overfunding and saturation.
